Page 266 - WSAVA2017
P. 266

266
An Urban Experience
although overusage may result in significant atrophy. Alternately, focal lesions may respond to topical tacrolimus applied once daily to every other day. In persistent, chronic or refractory cases, adjunctive immunosuppressive therapy may be required. These drugs may include cyclosporine, azathioprine, chlorambucil, dapsone, and sulfasalazine.
Table 1: Conditions known or suspected to cause vasculitis / vasculopathies in small animals
 Drugs
 Bacterial / Fungal
 Viral
  Rickettsial / protozoal
  Miscellaneous
   Vaccines
  S. aureus
    FIP
   RMSF
   Paraneoplastic
   Allergen immunotherapy
S. (pseud)intermedius
  Circovirus (dogs?)
 Ehrlichia
 Adverse food reaction
 Itraconazole
 E. coli verotoxin
   Anaplasma
  Insect bite
 Fenbendazole
 Bartonella
   Borrelia
  SLE, DLE and rheumatoid arthritis
 Cimetidine
 A. baumanii
   Toxoplasma
  Genetic / familal
 Carbamazole
  Histoplasma
     Babesia
   Photoaggravated/solar
   Meloxicam
        Atopic dermatitis?
   Human serum albumin
    Atherosclerosis and hypercholesterolemia
 Cephalexin
          Idiopathic
   +/- Firocoxib, Deracoxib
     Numerous others
           Selected references:
1. Innera M. Cutaneous vasculitis in small animals. The Veterinary clinics of North America Small animal practice. 2013;43(1):113-34.
2. Nichols PR, Morris DO, Beale KM. A retrospective study of canine and feline cutaneous vasculitis. Vet Dermatol. 2001;12(5):255-64.
3. Francis AH, Martin LG, Haldorson GJ, Lahmers KK, Luther TY, Alperin DC, et al. Adverse reactions suggestive of type III hypersensitivity in six healthy dogs given human albumin. J Am Vet Med Assoc. 2007;230(6):873-9.
4. Morris DO. Ischemic dermatopathies. The Veterinary clinics of North America Small animal practice. 2013;43(1):99-111.
5. Vitale CB, Gross TL, Magro CM. Vaccine-induced ischemic dermatopathy in the dog. Vet Dermatol. 1999;10:131-42.
6. Langford CA. Vasculitis. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S216- 25.
 42ND WORLD SMALL ANIMAL VETERINARY ASSOCIATION CONGRESS AND FECAVA 23RD EUROCONGRESS
  















































   264   265   266   267   268